Madrigal & Machicao LLC

Madrigal & Machicao LLC is a biopharmaceutical company dedicated to developing innovative therapeutics for metabolic dysfunction associated with steatohepatitis (MASH), a serious liver disease with significant unmet medical needs. Their pioneering research has led to the first and only FDA-approved treatment for MASH, aiming to halt or reverse liver scarring and prevent the severe complications associated with the disease.

With a focus on transforming the care of individuals living with MASH, Madrigal emphasizes its commitment to advancing medical solutions and improving patient outcomes. The company is at the forefront of addressing the chronic and progressive nature of MASH, which can lead to severe liver damage and is a leading cause of liver transplantation in the United States.

Generated from the website